Search

In the recent decade, nanoparticles (NPs) have had enormous implications in cancer biomedicine, including research, diagnosis, and therapy. However, their broad application still faces obstacles due to some practical limitations and requires further development. Recently, there has been more interest in the coated class of nanoparticles to address those challenges. Chitosan-coated NPs are simple to produce, biodegradable, biocompatible, exhibit antibacterial activity, and have less cytotoxicity. This study provides an updated and comprehensive overview of the application of chitosan-coated NPs as a promising class of NPs in cancer biomedicine. Additionally, we discussed chitosan-coated lipid, metal, and polymer-based nanoparticles in biomedical applications. Furthermore, different coating methods and production/characterization procedures were reviewed. Moreover, the biological and physicochemical advantages of chitosan-coated NPs, including facilitated controlled release, greater physicochemical stability, improved cell/tissue interaction, and enhanced bioavailability of medications, were highlighted. Finally, the prospects of chitosan-coated NPs in cancer biomedicine were discussed., (© 2024 Wiley Periodicals LLC.)

Glucose-responsive microneedle (MN) patches are of great interest for painless self-regulated insulin delivery in diabetic patients to improve their quality of life. This work is aimed to develop a smart MN-based insulin delivery system with potential for post-fabrication loading of insulin and a fast, repeatable response to glucose fluctuations without sacrificing its structural constituents. A hierarchically porous inorganic MN array is developed, consisting of a macroporous alumina core to provide an external access and a large capacity for insulin loading and a mesoporous shell to control insulin release by glucose-responsive gating of its nanopores that are dynamically capped with an enzyme-loaded chitosan (CS) hydrogel. The capped MNs doff their caps to blood sugar quickly and reversibly via swelling/deswelling of the CS cap. As a result, insulin release can be repeatedly regulated during sequential cycles of hyperglycemia/normoglycemia with short intervals of 40 min. In a type 1 diabetic mouse model, application of the smart MN system quickly causes normoglycemia within 1 h, which is prolonged for 5 h. Diabetic mice treated by the smart MN system behave similarly to the healthy mice in terms of controlled blood glucose levels during the in vivo glucose tolerance test. The "cap doffing" approach can aid the development of more safe, long-lasting MN systems for smart transdermal delivery of insulin and other drugs. • The porous MN array consists of a macroporous core and a gel-capped mesoporous shell. • The core provides large capacity and external access for on-demand insulin loading. • Insulin release is self-regulated via reversible gating of mesopores by gel swelling. • The system showed on/off insulin release in response to hyperglycemia/normoglycemia. • Diabetic mice treated by the smart MN system behaved similarly to the healthy mice. [ABSTRACT FROM AUTHOR]